PM
IMVT icon

Prosight Management’s Immunovant IMVT Stock Holding History

Prosight Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-175,825
Closed -$4.37M – 38
2026
Q1 		$4.37M Sell
175,825
-67,579
-28% -$1.75M 0.72% 27
2025
Q4 		$6.19M Sell
243,404
-455,068
-65% -$10.1M 1.28% 24
2025
Q3 		$11.3M Buy
698,472
+219,072
+46% +$3.55M 2.63% 18
2025
Q2 		$7.67M Buy
479,400
+119,400
+33% +$1.81M 1.87% 18
2025
Q1 		$6.15M Buy
360,000
+54,477
+18% +$1.14M 2.02% 21
2024
Q4 		$7.57M Sell
305,523
-64,477
-17% -$1.83M 2.09% 19
2024
Q3 		$10.5M Buy
370,000
+45,000
+14% +$1.33M 2.6% 17
2024
Q2 		$8.58M Buy
325,000
+130,000
+67% +$3.7M 2.56% 14
2024
Q1 		$6.3M Buy
+195,000
New +$7.11M 1.75% 17
2020
Q3 		– Sell
-95,500
Closed -$2.33M – 53
2020
Q2 		$2.33M Sell
95,500
-25,929
-21% -$556K 1% 29
2020
Q1 		$1.89M Sell
121,429
-103,273
-46% -$1.55M 0.88% 29
2019
Q4 		$3.57M Buy
+224,702
New +$2.52M 1.57% 20

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prosight Management's IMVT Position: Q2 2026 in Review

Prosight Management sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 175,825 shares — an estimated $4.37M sold.

Prosight Management first reported a position in IMVT in Q4 2019 and held it in 12 quarters. The position peaked at $11.3M in Q3 2025. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Prosight Management reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Prosight Management sold 175,825 Immunovant shares in Q2 2026, an estimated $4.37M.
  • Prosight Management first reported a position in Immunovant in Q4 2019 and held it in 12 quarters.
  • Prosight Management's Immunovant position peaked at $11.3M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.